Format

Send to

Choose Destination
ACS Synth Biol. 2014 Dec 19;3(12):944-8. doi: 10.1021/sb400174s. Epub 2014 Jan 14.

Engineering Escherichia coli for light-activated cytolysis of mammalian cells.

Author information

1
Department of Bioengineering, University of Pennsylvania , Philadelphia, Pennsylvania 19104, United States of America.

Abstract

By delivering payloads in response to specific exogenous stimuli, smart bacterial therapeutics have the potential to overcome many limitations of conventional therapies, including poor targeting specificity and dosage control in current cancer treatments. Although not yet explored as a trigger for bacterial drug delivery, light is an ideal induction mechanism because it offers fine spatiotemporal control and is easily and safely administered. Using recent advances in optogenetics, we have engineered two strains of Escherichia coli to secrete a potent mammalian cytotoxin in response to blue or red light. The tools in this study demonstrate the initial feasibility of light-activated bacterial therapeutics for applications such as tumor cytolysis, and their modular nature should enable simple substitution of other payloads of interest.

PMID:
24933444
PMCID:
PMC5264543
DOI:
10.1021/sb400174s
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center